Mobidiag Receives Second Tranche of €25M Financing from European Investment Bank

  • Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019
  • New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases

Mobidiag Ltd. today announces that it has received the second tranche of €10M from the €25M growth capital loan signed with the European Investment Bank Group (EIB) in May 2019. These new funds will be used to advance Mobidiag’s research and development and facilitate further validation and commercialisation of new molecular diagnostics tests using the Company’s Amplidiag® and Novodiag® platforms.

The loan is supported by the European Fund for Strategic Investments (EFSI), the main pillar of Investment Plan for Europe, through the European Growth Finance Facility (EGFF) initiative. This is the second operation between Mobidiag and EIB, following the first loan in 2016 for €15M.

Continue Reading

Mobidiag offers complete diagnostic solution for the detection of novel coronavirus infections with both PCR and antibody tests

  • CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release
  • Antibody test for detection of past COVID-19 infections
  • Secure supply chain and in-house manufacturing capabilities to meet demand

Mobidiag Ltd. today announces that it has received CE-IVD markings for its Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).

These tests complement the Company’s already available antibody test, Anti-SARS-CoV-2 Rapid Test, that Mobidiag is distributing from its joint venture partner in China, Autobio Diagnostics. Mobidiag is now able to commercially offer a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab based settings.

Continue Reading

Novodiag® COVID-19, a fully automated molecular diagnostic test, granted emergency use authorization in Finland for novel coronavirus

  • Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;
  • provides safety for users with a closed system;
  • easy to use with no need for highly trained personnel enabling decentralized testing.

Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received emergency use authorization in Finland for its Novodiag® COVID-19 molecular diagnostic test for the rapid and fully automated detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Novodiag® COVID-19 is now available for use in Finland*. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France.

Continue Reading

Amplidiag® COVID-19 molecular diagnostic test granted emergency use authorization in Finland for novel coronavirus

– Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance

– Currently set up for routine use in main Finnish clinical labs with capacity to test up to 4,000 samples per day

Mobidiag Ltd. announces that it has received emergency use authorization in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France. Mobidiag will register this test for CE-IVD mark and it should be available for widespread use in Europe in the coming weeks through Mobidiag’s sales teams and local distributors.

Continue Reading

NEW! Anti-SARS-CoV-2 Rapid Test now available

Mobidiag is now offering a rapid and easy to use immunoassay to detect coronavirus (COVID-19) infection.

The Anti-SARS-CoV-2 Rapid Test uses the lateral flow technology and allows detection of IgG and IgM from human serum, whole blood or plasma in about 15 minutes.

Developed by Autobio Diagnostics, key partner of Mobidiag and leading clinical diagnostics company in the Chinese the market, the Anti-SARS-CoV-2 test is now available through Mobidiag sales channels as well as our local distributors (except in Portugal, the Netherlands and Ukraine).

Continue Reading

Development of Novodiag® assay for safe and easy molecular testing of novel coronavirus and influenza viruses

Novodiag® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas

Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.

The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.

Continue Reading

Journal of Clinical Microbiology

J Clin Microbiol. 2020 Jan 29. doi:10.1128/JCM.01787-19
Diagnostic accuracy of a non-invasive test for the detection of Helicobacter pylori and resistance to clarithromycin in stool by Real-Time PCR Amplidiag® H. pylori + ClariR assay
Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux P-A, Vasseur P, Thiebault Q, Lefèvre C, Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C
Learn more about Amplidiag® H. pylori + ClariR assay

Continue Reading

Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test

ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).

Continue Reading

Mobidiag Symposium on Innovative Molecular Diagnostics to be held for Third year at RICAI Annual Meeting

PARIS, France, December 11th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, will host a symposium at the 39th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI) conference in Paris, from the 16th to 17th of December.

The RICAI conference is an annual meeting bringing together leading French clinicians and microbiologists (parasitologists, virologists, bacteriologists) and innovative commercial companies in diagnostics.

Continue Reading

Mobidiag Appoints Joseph Bernardo as Senior Strategic Advisor

ESPOO, Finland, December 10, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the appointment of Joseph E. Bernardo as Senior Strategic Advisor to the Company.

Mr. Bernardo has over twenty years of experience in the diagnostics industry including a significant tenure as a President at Thermo Fisher Scientific, working across a number of divisions including Clinical Next-Generation Sequencing and Oncology, Immuno-Diagnostics, Anatomic Pathology and Fisher HealthCare, the hospital laboratory distribution business of Thermo Fisher.

Continue Reading